Hepa-Merz gran. prigot. r-ra d / int. reception 3g / 5g pack. # 10

Clinical and pharmacological group: Drug for the treatment of liver diseases

Pharmaco-therapeutic group: Drug for the treatment of liver diseases

pharmachologic effect

It has a detoxifying effect, reducing the increased level of ammonia in the body, in particular in liver diseases.

The action of the drug is associated with its participation in the ornithine cycle of Krebs urea formation (activates the cycle, restoring the activity of liver cell enzymes - ornithine carbamoyltransferase and carbamoyl phosphate synthetase).

Promotes the production of insulin and growth hormone.

Improves protein metabolism in diseases requiring parenteral nutrition.

It helps to reduce asthenic, dyspeptic and pain syndromes, as well as to normalize increased body weight (with steatosis and steatohepatitis).

Pharmacokinetics

L-ornithine-L-aspartate rapidly dissociates into ornithine and aspartate and begins to act within 15-25 minutes, having a short T1 / 2.

It is excreted in the urine through the urea cycle.

Indications

acute and chronic liver diseases, accompanied by hyperammonemia

hepatic encephalopathy (latent or severe)

steatosis and steatohepatitis of various origins.

ICD-10 codes

Dosage regimen

The drug is taken orally, 1-2 sachets of granules, dissolved in 200 ml of liquid, 3 times / day, after meals.

The duration of the course depends on the severity of the disease.

Side effect

From the digestive system: infrequently - nausea, vomiting, abdominal pain, flatulence, diarrhea.

From the musculoskeletal system: very rarely - pain in the limbs.

Sunset yellow dye can cause allergic reactions.

Contraindications for use

severe renal failure (serum creatinine> 3 mg / 100 ml)

lactation period

children's age (due to insufficient data)

hypersensitivity to drug components.

The drug should be prescribed with caution during pregnancy.

Application during pregnancy and lactation

The drug should be used with caution during pregnancy.

The drug is contraindicated for use during lactation.

Application for violations of liver function

The drug is used according to indications.

Application for impaired renal function

The drug is contraindicated in severe renal failure (creatinine index 3 mg / 100 ml).

Application in children

The use of the drug is contraindicated in childhood (due to insufficient data).

special instructions

Influence on the ability to drive vehicles and use mechanisms

When establishing a diagnosis of hepatic encephalopathy due to the underlying disease, patients should be careful when driving vehicles and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Overdose

Symptoms: increased severity of side effects.

Treatment: gastric lavage, intake of activated carbon, symptomatic therapy.

Drug interactions

Interaction with other medicinal products has not been described.

Storage conditions and periods

The drug should be stored out of the reach of children at a temperature not exceeding 25 ° C.

The shelf life is 5 years.

Terms of dispensing from pharmacies

The drug is dispensed without a prescription.

Name ENG

HEPA-MERZ

Clinical and pharmacological group

Drug for the treatment of liver diseases

ATX code

Drugs for the treatment of liver diseases

Dosage

3g x 5g

Structure

Active ingredients: Canadian aspen (Populus) D1 - 7 ml

saw palm (Sabal) D6 - 10 ml

spotted hemlock (Conium) D6 - 10 ml

potassium iodide (Kalium iodatum) D12 - 10 ml

iron picrate (Ferrum picrinicum) D12 - 10 ml.

Excipient: ethyl alcohol (ethanol) 43% (by weight) - 53 ml.

Indications

Acute and chronic liver diseases, accompanied by hyperammonemia

hepatic encephalopathy (latent or severe)

steatosis and steatohepatitis of various origins.

INN / Active ingredient

L-Ornithine L-Aspartate

Storage conditions and periods

The drug should be stored out of the reach of children at a temperature not exceeding 25 ° C.

The shelf life is 5 years.

Contraindications

Severe renal failure (serum creatinine> 3 mg / 100 ml)

lactation period

children's age (due to insufficient data)

hypersensitivity to drug components.

The drug should be prescribed with caution during pregnancy.

Specifications

Category

Hepatoprotectors

Scope of the drug

Gastrointestinal tract

Release form

Granules

Manufacturer country

Germany

Package quantity, pcs

ten

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Merz Pharma GmbH & Co.KGaA. / B.B

The amount of the dosage form in the primary package

5 g

Primary packaging type

Sachet (sachet)

Type of consumer packaging

Cardboard box

Dosage form

Granules for preparation of oral solution

Expiration date in days

60

Dosage (volume) of the substance in the preparation

ornithine aspartate 3 g

Package weight, g

25

Mode of application

:

The drug is taken orally 1-2 sachets of granules, dissolved in 200 ml of liquid, 3 times / day, after meals. < br> < br> The duration of the course depends on the severity of the disease.